March 23, 2020
Takeda’s strategy is to secure product supply continuity for patients through managing adequate levels of inventory and/or alternative suppliers for the production of our medicines. This strategy is generally applied across our global supply chain for key starting materials, excipients, raw materials, APIs, and finished products.
Based on current assessments of our global supply chain, we do not anticipate any potential supply disruption in the near-term due to the Coronavirus outbreak. Longer-term, it is not yet possible to predict precisely what the impact may be on individual products. We will continue to monitor the situation as it evolves and take all necessary actions in an effort to ensure supply continuity for the people we serve.